List view / Grid view
30 July 2014 | By Pfizer
Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million...
18 July 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...
17 July 2014 | By Pfizer
Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B...
10 July 2014 | By Pfizer
CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health...
2 July 2014 | By Pfizer
Pfizer Inc. announced that the Orthodox Union has granted kosher certification to ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease...
27 June 2014 | By Pfizer
The board of directors of Pfizer Inc. declared a 26-cent third-quarter 2014 dividend on the company’s common stock...
23 June 2014 | By Pfizer
Adults 65 or older can now be immunized with the same Pneumococcal Conjugate Vaccine used in children...
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
16 June 2014 | By Pfizer
Pfizer Inc. announced the opening of a new 280,000 square-foot Research and Development hub in Cambridge, Mass...
11 June 2014 | By Pfizer
Additional data further characterizes the safety profile of XELJANZ...
30 May 2014 | By Pfizer
Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research...
28 May 2014 | By Pfizer
The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide...
20 May 2014 | By AstraZeneca
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal, comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014...
16 May 2014 | By Pfizer
Public health initiative aims to increase unacceptably low adult vaccination rates...
13 May 2014 | By Astrazeneca
The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc. earlier...
